Background: Michigan’s legal protections for drugs produced in compliance with the rigorous approval process of the U.S. Food and Drug Administration must remain in place. Litigation costs drive up health care costs, and hinder the ability of Michigan’s manufacturers to compete on the basis of cost.

MMA Position: MMA opposes efforts to erode Michigan’s current tort protections.